Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
SEPN submitted a Form 144 notice for a proposed sale of 11,798 shares tied to an exercise of stock options to be executed on 05/26/2026. The filing also discloses prior 10b5-1 sales by Samira Shaikhly of 70,453 shares on 03/02/2026 for $1,979,835.21.
The sale is reported through Morgan Stanley Smith Barney LLC with cash settlement; the excerpt shows a proceeds figure of $334,591.28 associated with the 11,798-share transaction. Transaction mechanics and timing are stated in the notice.
Septerna reported strong top-line growth for the three months ended March 31, 2026, with revenue of $26.5 million driven by its Novo Nordisk collaboration, compared with $0.2 million a year earlier. Revenue included recognition of upfront, research and milestone consideration under the agreement.
Research and development expense rose to $29.5 million and general and administrative expense to $10.3 million, reflecting pipeline expansion and public-company costs. Net loss narrowed to $8.6 million from $21.5 million, helped by collaboration revenue and $5.0 million of interest income.
Septerna ended the quarter with $522.1 million in cash, cash equivalents and marketable securities and deferred revenue of $152.0 million, and expects this liquidity to fund operations at least into 2029. The company also initiated a Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with data anticipated in late 2026 or early 2027.
Septerna, Inc. reported first quarter 2026 results showing a sharp rise in collaboration revenue and a narrower loss as it advanced multiple clinical programs. Revenue was $26.5 million for the quarter ended March 31, 2026, driven by its Novo Nordisk partnership, compared to $0.2 million a year earlier.
Research and development expenses increased to $29.5 million and general and administrative expenses to $10.3 million, reflecting pipeline growth. Net loss improved to $8.6 million from $21.5 million, and cash, cash equivalents and marketable securities totaled $522.1 million, which the company expects will fund operations at least into 2029. Septerna highlighted positive Phase 1 data for SEP-631 in mast cell-driven diseases and the start of a Phase 1 trial for SEP-479 in hypoparathyroidism, alongside continued work on its TSHR NAM and Novo Nordisk collaboration programs.
Septerna, Inc. is calling a virtual-only 2026 Annual Meeting of Stockholders on June 26, 2026, at 2:00 p.m. Pacific Time. Stockholders of record as of April 29, 2026, when 44,949,189 common shares were outstanding, may attend online, vote and submit questions using a 16‑digit control number.
Owners will vote on electing two Class II directors to serve until the 2029 annual meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting “FOR” both proposals.
Septerna is using the SEC’s “Notice and Access” rules to deliver proxy materials electronically and remains an emerging growth company, relying on scaled disclosure requirements and not holding advisory votes on executive compensation or pay‑versus‑performance at this time.
Septerna, Inc. President and COO Elizabeth Bhatt exercised stock options and sold shares in a planned transaction. She exercised options for 4,000 shares of Common Stock at an exercise price of $6.81 per share, then sold the same 4,000 shares in open-market trades at weighted average prices between about $23.33 and $25.91. The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 20, 2025. Following these transactions, she directly owned 174,535 shares of Common Stock.
Septerna, Inc. has begun a Phase 1 clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism. The randomized, placebo-controlled study in healthy adults includes single-ascending and multiple-ascending dose cohorts, with enrollment of up to approximately 150 participants in Australia.
The trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics, including effects on endogenous parathyroid hormone and serum calcium, and includes a crossover food-effect study. Septerna anticipates reporting SAD/MAD data in late 2026 or early 2027. SEP-479 aims to offer once-daily oral PTH replacement based on supportive preclinical data.
Septerna, Inc. files a Form S-3ASR and launches an at-the-market equity program registering up to $150,000,000 of common stock. The company may sell shares from time to time under a sales agreement with BofA Securities, Inc. dated March 10, 2026, including sales directly to the agent as principal.
Septerna describes its business as a clinical-stage biotechnology company focused on GPCR oral small-molecule drug discovery using its Native Complex Platform®. The prospectus states shares outstanding were 44,806,272 as of December 31, 2025.
Septerna, Inc. filed its Annual Report describing a clinical‑stage GPCR-focused biotech with multiple oral small‑molecule programs and a new large collaboration. The company highlights lead candidates SEP‑479 for hypoparathyroidism and SEP‑631 for chronic spontaneous urticaria, plus an early TSHR program for Graves’ disease and thyroid eye disease.
Septerna reports a global collaboration with Novo Nordisk to discover oral metabolic drugs across five GPCR targets, including GLP‑1, GIP and glucagon receptors, with a $195.0 million upfront payment and potential per‑program milestones of about $498.0 million plus tiered royalties. As of March 2, 2026, it had 44,906,374 common shares outstanding and non‑affiliate market value of about $363.3 million as of June 30, 2025.
The filing emphasizes that Septerna has a limited operating history, expects significant ongoing losses, and will require substantial additional funding. It details extensive clinical, regulatory, manufacturing and competitive risks typical of early‑stage biotech, while positioning its Native Complex Platform® as the core engine for future pipeline growth.
Septerna, Inc. reported strong fourth quarter and full year 2025 results alongside major pipeline progress. Revenue rose to $24.1 million in the fourth quarter of 2025 and $46.0 million for the full year, up sharply from $0.2 million and $1.1 million in 2024, primarily reflecting collaboration work and amortization of a Novo Nordisk upfront payment.
The company recorded a net loss of $10.7 million for the quarter and $48.9 million for 2025, narrowing from $20.7 million and $71.8 million in 2024, as higher revenue partially offset increased R&D and G&A expenses. Cash, cash equivalents, and marketable securities were $548.7 million as of December 31, 2025, and the cash runway is expected to fund operations at least into 2029.
Clinically, Septerna reported compelling Phase 1 data for SEP-631 in mast cell diseases, supporting Phase 2b development in chronic spontaneous urticaria in the second half of 2026, and is advancing SEP-479 toward a Phase 1 trial in the first half of 2026, while continuing progress on its TSHR NAM and discovery programs.